Straumann Roxolid Multi-Center Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Institut Straumann AG
Sponsor:
Information provided by (Responsible Party):
Institut Straumann AG
ClinicalTrials.gov Identifier:
NCT01842958
First received: April 23, 2013
Last updated: April 11, 2014
Last verified: April 2014
  Purpose

The primary objective of this study is to demonstrate non-inferiority of the Straumann Bone Level Ø 3.3 mm NC SLActive Roxolid Implants compared to Straumann Bone Level Ø 4.1 mm RC SLActive Roxolid Implants based on mean crestal bone level changes measured between surgery and 12 months post-implant placement. The secondary objectives will assess differences in clinical outcomes between the test and control implants, including implant success and survival, gingival recession, subject satisfaction and additional early bone level measurements.


Condition Intervention
Jaw, Edentulous, Partially
Device: Roxolid dental implant, 4.1 mm diameter
Device: Roxolid dental implant, 3.3 mm diameter

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Multi-center Clinical Study Evaluating the Crestal Bone Level Change of Straumann Bone Level Ø 3.3 mm NC SLActive Roxolid Implants Compared to Straumann Bone Level Ø 4.1 mm RC SLActive Roxolid Implants for Single Tooth Replacement in the Anterior and Pre-molar Region

Further study details as provided by Institut Straumann AG:

Primary Outcome Measures:
  • Mean crestal bone level change [ Time Frame: 12 months post loading ] [ Designated as safety issue: No ]
    Mean crestal bone level change between implant placement and 12 months post loading as determined by radiographic measurement of mesial and distal bone levels following placement of a Straumann Bone Level Ø3.3 mm NC SLActive Roxolid Implant versus a Straumann Bone Level Ø4.1 mm RC SLActive Implant in the anterior or pre-molar region of the mandible or maxilla.


Secondary Outcome Measures:
  • Additional mean crestal bone level changes [ Time Frame: 25 days, 6 months post loading, and 12 months post loading ] [ Designated as safety issue: No ]
    Additional radiographic evaluation of mesial and distal crestal bone level changes between implant placement and at 25 days post post implant placement, 6 months post loading, and 12 months post loading

  • Implant success rate [ Time Frame: 25 days, 6 months post loading, and 12 months post loading ] [ Designated as safety issue: No ]
  • Implant survival rate [ Time Frame: 7 days, 25 days, 6 months post loading, and 12 months post loading ] [ Designated as safety issue: No ]
  • Gingival recession [ Time Frame: 6 months post loading and 12 months post loading ] [ Designated as safety issue: No ]
  • Incidence of adverse events and adverse device effects [ Time Frame: Surgical visit, 7 days, 25 days, 6 months post loading, and 12 months post loading ] [ Designated as safety issue: Yes ]
  • Subject satisfaction [ Time Frame: 12 months post loading ] [ Designated as safety issue: No ]
    Subject satisfaction will be assessed utilizing Visual Analogs Scales (VAS)


Estimated Enrollment: 50
Study Start Date: March 2013
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Roxolid dental implant, 4.1 mm diameter
Straumann Bone Level Ø4.1 mm RC SLActive Roxolid Implant available in lengths 8mm, 10mm, 12mm and 14mm
Device: Roxolid dental implant, 4.1 mm diameter
Placement of the Straumann Bone Level Ø4.1 mm RC SLActive Roxolid Implant available in lengths 8mm, 10mm, 12mm, and 14mm for single tooth replacement in the anterior and pre-molar region.
Experimental: Roxolid dental implant, 3.3 mm diameter
Straumann Bone Level Ø3.3 mm NC SLActive Roxolid Implant available in 8mm, 10mm, 12mm, and 14mm
Device: Roxolid dental implant, 3.3 mm diameter
Placement of Straumann Bone Level Ø3.3 mm NC SLActive Roxolid Implant available in 8mm, 10mm, 12mm, and 14mm for single tooth replacement in the anterior and pre-molar region.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects must have voluntarily signed the informed consent form
  • Subjects must be males or females who are a minimum of 20 years of age
  • Subjects must have a single tooth gap in the pre-molar or anterior region of the mandible or maxilla (ADA tooth positions 4-13 and 20-29; FDI tooth positions 11-15, 21-25, 31-35, and 41-45)
  • Subjects must have opposing dentition (natural teeth, fixed or removable restorations)
  • Subjects must have a full mouth plaque score ≤ 25%, according to O'Leary, at the time of screening
  • Subjects must have adequate bone to encapsulate the implant and allow placement of an Ø 4.1 mm Bone Level Implant.
  • Adequate bone height of at least 1 mm longer than the length of the study implant
  • Subjects must have substantially healed (at least 16 weeks after tooth extraction) extraction sockets
  • Subjects must be committed to the study and the required follow-up visits
  • Subjects must be in good general health as assessed by the Investigator

Exclusion Criteria:

  • Subjects with a systemic disease that would preclude dental implant surgery (e.g. serious internal medical problems, disorders of bone metabolism, uncontrolled bleeding disorders, weakened immune system, illness requiring periodic use of steroids, uncontrollable endocrine disorders, uncontrolled diabetes)
  • Subjects with any contraindications for oral surgical procedures (e.g. inadequate wound healing capacity, poor oral hygiene, maxillary and mandibular growth not completed, xerostomia)
  • Subjects with mucosal diseases (e.g., erosive lichen planus) in the localized area around the study implant site
  • Subjects with a history of local irradiation therapy in the head/neck area
  • Subjects with any untreated endodontic lesions or untreated periodontal disease adjacent to the implant site
  • Subjects receiving, or having a history of receiving, intravenous or subcutaneous antiresorptive agents, such as bisphosphonates
  • Subjects with severe bruxing, parafunctional habits, or temporomandibular joint dysfunction
  • Subjects with existing implants in the adjacent positions to the planned implant site
  • Subjects requiring bone augmentation or socket grafting within 6 months prior to surgery
  • Subjects requiring more than minimal simultaneous augmentation for minimal buccal dehiscence defects (defect cannot be greater than 3mm in height)
  • Subjects with inadequate oral hygiene or who are unmotivated for adequate home care
  • Subjects who have physical or mental handicaps that would interfere with the ability to perform adequate oral hygiene
  • Subjects who are pregnant or intending to become pregnant during the duration of the study
  • Subjects who are heavy smokers (defined as >10 cigarettes per day or >1 cigar per day) or chew tobacco
  • Subjects who abuse alcohol or drugs
  • Subjects who have undergone administration of any investigational device within 30 days of enrollment in the study
  • Subjects with conditions or circumstances, in the opinion of the Investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01842958

Contacts
Contact: Kelly Jork, MS 978-747-2533 kelly.jork@straumann.com

Locations
United States, California
UCLA School of Dentistry Recruiting
Los Angeles, California, United States, 90095-1668
Contact: Tara L. Aghaloo, DDS, MD, PhD    310-794-7070    taghaloo@dentistry.ucla.edu   
Principal Investigator: Tara L. Aghaloo, DDS, MD, PhD         
United States, Massachusetts
Boston University, School of Dental Medicine Recruiting
Boston, Massachusetts, United States, 02118
Contact: Serge Dibart, DDS, DMD    617-638-4762    sdibart@bu.edu   
Principal Investigator: Serge Dibart, DDS, DMD         
United States, New York
New York University College of Dentistry Active, not recruiting
New York, New York, United States, 10019-5404
United States, Texas
Univeristy of Texas Health Science Center San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Guy Huynh-Ba, DDS    210-567-3604    huynhba@uthsca.edu   
Principal Investigator: Guy Huynh-Ba, DDS         
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 98195-7444
Contact: Robert B. O'Neal, DMD    206-915-9178    rboneal@uw.edu   
Principal Investigator: Robert B. O'Neal, DMD         
Sponsors and Collaborators
Institut Straumann AG
Investigators
Principal Investigator: David L. Cochran, DDS, MS, PhD University of Texas Health Science Center San Antonio
  More Information

No publications provided

Responsible Party: Institut Straumann AG
ClinicalTrials.gov Identifier: NCT01842958     History of Changes
Other Study ID Numbers: CR 10/09
Study First Received: April 23, 2013
Last Updated: April 11, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Institut Straumann AG:
Dental Implant

Additional relevant MeSH terms:
Jaw, Edentulous
Jaw, Edentulous, Partially
Mouth, Edentulous
Jaw Diseases
Musculoskeletal Diseases
Stomatognathic Diseases
Mouth Diseases
Tooth Diseases

ClinicalTrials.gov processed this record on August 28, 2014